DSS files registration statement on Form S-1

DSS has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of the Company’s wholly-owned subsidiary, Impact Biomedical. DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions. The Company has engaged Aegis Capital as the exclusive placement agent for the registered direct offering. A registration statement on Form S-1 relating to these securities has been filed with the SEC and has yet to become effective.